These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10692755)

  • 1. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Chik G; Crook MA
    Int J Clin Pract; 1999 Dec; 53(8):609-11. PubMed ID: 10692755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
    Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
    Athyros VG; Papageorgiou AA; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2001; 17(4):267-72. PubMed ID: 11922400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Chik G
    Int J Clin Pract; 2001 Dec; 55(10):673-5. PubMed ID: 11777291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
    Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
    J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
    Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
    van Wissen S; Smilde TJ; de Groot E; Hutten BA; Kastelein JJ; Stalenhoef AF
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):451-5. PubMed ID: 14671468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.